Skip to main content

Speakers

Thomas Byrne

Thomas Byrne

President & CEO

The Korea Society

Claire Callahan

Claire Callahan

Communications Officer

The Korea Society

Irene Kyoung

Irene Kyoung

Research Associate, Korea Program

Walter H. Shorenstein Asia-Pacific Research Center, Stanford University

Salome Da Silva Duarte Lepez

Salome Da Silva Duarte Lepez

International Health Law, COVID Vaccine Policy & Biostatistics

Johns Hopkins Bloomberg School of Public Health, MPH ’22

Speakers

Clint Work

Clint Work

Fellow and Director of Academic Affairs

Korea Economic Institute of America

Event Details

October 27, 2022 3:00 PM – 4:00 PM ET
Livestream via YouTube
Academic Paper Series

Early in the pandemic, South Korea drew widespread praise for the speed and efficiency of its response to slowing the spread of the virus and saving lives. However, despite this initial success, South Korea faced vaccine nationalism and other access challenges in its effort to secure Covid-19 vaccines. Spurred by these challenges, South Korea established a national strategic policy to become a global vaccine hub, not only to meet the current and future public health needs of its own population but also to assist low- and middle-income countries (LMICs) facing even starker obstacles in accessing safe and effective vaccines.

Please join KEI for a discussion with the Thomas Byrne, Claire Callahan, Irene Kyoung, and Salome Da Silva Duarte Lepez about how global vaccine access and equity was hindered by the shortcomings of national and bilateral vaccine diplomacy and multilateral mechanisms during the Covid-19 pandemic, and how South Korea’s demonstrated capabilities to rise as global vaccine development, manufacturing and training hub will help bolster global public health capacities in the future.